Valion Bio Advances Entolimod to U.S. Government-Funded Efficacy Study

• Valion Bio's Entolimod will enter a fully NIAID-funded therapeutic efficacy study at the Armed Forces Radiobiology Research Institute.
• The study will assess survival following radiation-induced gastrointestinal injury; top-line results are expected in early December.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-008221), on November 02, 2026, and is solely responsible for the information contained therein.